The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass
NCT ID: NCT01410617
Last Updated: 2013-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2011-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration
NCT02576873
Prevention and Management of Cardiovascular and Cerebrovascular Complications in Maintenance Hemodialysis (MHD) Patients
NCT07335471
Carotid Intima-media Thickness as Cardiovascular Mortality Predictor in Peritoneal Dialysis Patients
NCT02938767
In-Centre Nocturnal Hemodialysis (INHD): A Long-Term Follow-Up Study
NCT02684773
Hemodialysis in the Elderly (70yrs & Older)
NCT03065972
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dialysis
the patients who undergo 3 sessions prophylactic hemodialysis
hemodialysis
3 sessions hemodialysis before CABG
control group
the patients who do not undergo hemodialysis
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hemodialysis
3 sessions hemodialysis before CABG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ckd patients with stage 3,4
* CABG for the first time
Exclusion Criteria
* previous CABG (coronary artery bypass grafting)
* AKI(acute kidney injury)
* dialysis patients
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Imam Khomeini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Reza Khatami
Member of research board of Nephrology ResearchCenter of Tehran University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roghieh Borji, MD
Role: PRINCIPAL_INVESTIGATOR
Imam Khomeini Hospital
Mohammad R Khatami, MD
Role: STUDY_DIRECTOR
Nephrology research Center
Seyyed Hossein Ahmadi, MD
Role: STUDY_CHAIR
Tehran Herat Center
Khosro Barkhordari, MD
Role: PRINCIPAL_INVESTIGATOR
Tehran Heart Center
Mohammad R Abbasi, MD
Role: PRINCIPAL_INVESTIGATOR
Nephrology Researc Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tehran Herat Center
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THC-473
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.